The comparative effects of n-3 and n-6 polyunsaturated fatty acids on plasma fibrinogen levels: a controlled clinical trial in hypertriglyceridemic subjects.

References

• Meade TW, Brozovic M, Chakrabarti RR, Haines APet al.: Haemostatic function and ischaemic heart disease: principal results of the Northwick Park heart study. Lancet 2: 533–537, 1986.
   PubMed Web of Science ®Google Scholar
• Wilhemsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G: Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 311: 501–505, 1984.
   PubMed Web of Science ®Google Scholar
• Kannel WB, Wolf PA, Castelli WP, D'Agostino RB: Fibrinogen and risk of cardiovascular disease. The Framingham study. JAMA 258: 1183–1186, 1987.
   PubMed Web of Science ®Google Scholar
• Welin L, Svardsudd K, Wilhelmsen L, Larsson B, Tibblin G: Analysis of risk factors for stroke in a cohort of men born in 1913. N Engl J Med 317: 521–526, 1987.
   PubMed Web of Science ®Google Scholar
• Smith EB: Fibrinogen, fibrin and fibrin degradation products in relation to atherosclerosis. Clin Haemotol 15: 355–370, 1986.
   PubMedGoogle Scholar
• Merrill EW: Rheology of blood. Physiol Rev 49: 863–887, 1969.
   PubMed Web of Science ®Google Scholar
• Lowe GDO, Drummond MM, Third JLHet al.: Increased plasma fibrinogen and platelet aggregates in type II hyperlipoproteinemia. Thromb Haemost 42: 1503–1507, 1979.
   Web of Science ®Google Scholar
• Bini A, Fenoglio JJ Jr, Mesa-tegada R, Kudryk B, Kaplan KL: Identification and distribution of fibrinogen, fibrin, and fibrin(ogen)-degradation products in atherosclerosis: use of monoclonal antibodies. Arteriosclerosis 9: 109–121, 1989.
   PubMedGoogle Scholar
• Ishida T, Tanaka K: Effects of fibrin and fibrinogen-degradation products on the growth of rabbit aortic smooth muscle cells in culture. Atherosclerosis 44: 161–174, 1982.
   PubMedGoogle Scholar
• Homstra G: Effect of dietary lipids on arteriothrombus formation: rationale for the support of drug therapy by diet. Sem Thromb Hemost 14: 59–65, 1988.
   PubMedGoogle Scholar
• Radack KL, Deck C, Huster G: Dietary supplementation with low dose fish oils lowers fibrinogen levels: a randomized, double-blind controlled study. Ann Intern Med 111: 757–758, 1989.
   PubMedGoogle Scholar
• Simpson HCR, Mann JI, Meade TWet al.: Hypertriglyceridaemia and hypercoagulability. Lancet 1: 786–789, 1983.
   PubMed Web of Science ®Google Scholar
• Hostmark AT, Bjerkedal T, Kierulf P, Flaten H, Ulshagen K: Fish oil and plasma fibrinogen. Br Med J 297: 180–181, 1988.
   PubMed Web of Science ®Google Scholar
• Schmidt EB, Kristensen SB, Dyerberg J: The effect of fish oil on lipids, coagulation and fibrinolysis in patients with angina pectoris. Artery 15: 316–329, 1988.
   PubMedGoogle Scholar
• Mortensen JZ, Schmidt EB, Nielsen AH, Dyerberg J: The effects of n-6 and n-3 polyunsaturated fatty acids on hemostasis, blood lipids and blood pressure. Thromb Haemost 50: 543–546, 1983.
   PubMed Web of Science ®Google Scholar
• Deck C, Radack K: The effect of modest doses of omega-3 fatty acids on lipids and lipoproteins in hypertriglyceridemic subjects: a randomized controlled trial. Arch Intern Med 149: 1857–1862, 1989.
   PubMedGoogle Scholar
• Fredrickson DS, Levy RI: Familial hyperlipoproteinemia. In Stanberry JB, Wyngaarden JB, Fredrickson DS (eds): “Metabolic Basis of Inherited Disease,” 3rd ed. New York: McGraw-Hill, pp 545–614, 1972.
   Google Scholar
• Rogers S, James KS, Butland BK, Etherington MD, O'Brien JR, Jones JG: Effects of a fish oil supplement on serum lipids, blood pressure, bleeding time, hemostatic and rheological variables: a double blind randomized controlled trial on healthy volunteers. Atherosclerosis 63: 137–143, 1987.
   PubMed Web of Science ®Google Scholar
• Haines AB, Sanders TAB, Imeson JDet al.: Effects of a fish oil supplement on platelet function, haemostatic variables, and albuminuria in insulin-dependent diabetics. Thromb Res 43: 643–655, 1986.
   PubMed Web of Science ®Google Scholar
• Bydlowski SP, Yunker RL, Subbiah MTR: Ontogeny of 6-keto PGF, synthesis in rabbit aorta and the effect of premature weaning. Am J Physiol 252: H14–H21, 1987.
   Google Scholar
• Meade TW, Imeson J, Stirling Y: Effects of changes in smoking and other characteristics on clotting factors and the risk of ischemic heart disease. Lancet 2: 986–988, 1987.
   PubMed Web of Science ®Google Scholar
• Vermylen C, de Vreker RA, Verstraete M: A rapid enzymatic method for assay of fibrinogen fibrin polymerization time (FPT test). Clin Chim Acta 8: 418–424, 1963.
   PubMed Web of Science ®Google Scholar
• Kluft C: Studies on the fibrinolytic system in human plasma; quantitative determination of plasminogen activators and proactivators. Thromb Haemost 41: 365–383, 1979.
   PubMed Web of Science ®Google Scholar
• Glas-Greenwalt P, Kant KS, Allen C, Pollak VE: Fibrinolysis in health and disease. Severe abnormalities in systemic lupus erythematosus. J Lab Clin Med 104: 962–976, 1984.
   PubMed Web of Science ®Google Scholar
• Glas-Greenwalt P, Hall JM, Panke TW, Kant KS, Allen CM, Pollak VE: Fibrinolysis in health and disease: abnormal levels of plasminogen activator, plasminogen activator inhibitor, and protein C in thrombotic thrombocytopenic purpura. J Lab Clin Med 108: 415–422, 1986.
   PubMedGoogle Scholar
• Laurell CB: Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 15: 45, 1966.
   PubMed Web of Science ®Google Scholar
• Abildgaar U, Lie M, Oodegard OR: Antithrombin (heparin cofactor) assay with “new” chromogenic substrates (S-2238 and Chromozym THN). Thromb Res 11: 549–553, 1977.
   PubMedGoogle Scholar
• Hills M, Armitage P: The two-period crossover clinical trial. Br J Clin Pharmacol 8: 7–20, 1979.
   PubMed Web of Science ®Google Scholar
• Goodnight SH: The antithrombic effects of fish oil. In Simopoulos AP, Kifer RR, Martin RE (eds): “Health Effects of Polyunsaturated Fatty Acids in Seafoods.” New York: Academic, pp 135–149, 1989.
   Google Scholar
• Elkeles RS, Chakrabarti R, Vickers MV, Stirling Y, Meade TW: Effect of treatment of hyperlipidaemia on haemostatic variables. Br Med J 281: 973–974, 1980.
   PubMed Web of Science ®Google Scholar
• Schmidt EB, Kristensen ST, Sorensen PJ, Dyerberg J: Antithrombin III and protein C in stable angina pectoris — influence of dietary supplementation with polyunsaturated fatty acids. Scand J Clin Lab Invest 48: 469–473, 1988.
   PubMed Web of Science ®Google Scholar
• Aimer LO, Kjellstrom T: The fibrinolytic system and coagulation during bezafibrate treatment of hypertriglyceridemia. Atherosclerosis 61: 81–85, 1986.
   PubMedGoogle Scholar
• Colvin RB, Dvorak HF: Fibrinogen/fibrin on the surface of macrophages. Detection, distribution, binding requirements, and possible role in macrophage adherence phenomena. J Exp Med 142: 1377–1390, 1975.
   PubMedGoogle Scholar
• Sherman LA, Lee J: Specific binding of soluble fibrin to macrophages. J Exp Med 145: 76–85, 1977.
   PubMedGoogle Scholar
• Hogg N: Human monocytes are associated with the formation of fibrin. J Exp Med 157: 473–485, 1983.
   PubMedGoogle Scholar
• Hansen JB, Olsen JO, Wilsgard L, Osterud P: Effects of dietary supplementation with cod liver oil on monocyte thromboplastin synthesis, coagulation, and fibrinolysis. J Intern Med 225(Suppl 1):133–139, 1989.
   Google Scholar
• Sperling RI, Robin J-L, Kylander KAet al.: The effects of n-3 polyunsaturated fatty acids on the generation of platelet-activating factor-acether by human monocytes. J Immunol 139: 4186–4191, 1987.
   PubMed Web of Science ®Google Scholar
• Schmidt EB, Dyerberg J: n-3 fatty acids and leukocytes. J Intern Med 225(Suppl 1):151–158, 1989.
   Web of Science ®Google Scholar